Media Interviews Online Articles

22

Jul2008
ATLANTA, July 22 /PRNewswire-FirstCall/ — Shire Limited , the global specialty biopharmaceutical company, today announced that it has launched VYVANSE(TM) (lisdexamfetamine dimesylate) for the treatment of adults with Attention Deficit Hyperactivity Disorder (ADHD). This launch follows the recent FDA approval of VYVANSE to treat ADHD in the adult population. VYVANSE ... Read More

07

Jul2008
MONDAY, July 7 (HealthDay News) -- Children with attention-deficit hyperactivity disorder (ADHD) are at a 50 percent higher risk for being overweight if they are not taking medication for the condition, a new study finds. On the other hand, youngsters who were medicated for ADHD had a raised risk of being ... Read More

27

May2008
TUESDAY, May 27 (HealthDay News) -- Adults with attention deficit hyperactivity disorder (ADHD) miss, on average, more than three weeks a year in workplace productivity, according to a new global reckoning of the problem. Altogether, between 3 percent and 4 percent of adults worldwide have ADHD, according to survey data from ... Read More

27

Apr2008
NEW YORK -- April 24, 2008 -- The US Food and Drug Administration (FDA) has approved lisdexamfetamine dimesylate (Vyvanse) for the treatment of attention-deficit/hyperactivity disorder (ADHD) in adults. Introduced in July 2007 for the treatment of ADHD in children aged 6 to 12 years, lisdexamfetamine is the first and only ... Read More
April 27, 2008David W. Goodman, MD

10

Jul2006
Like many young mothers, Sophie Currier is a busy woman. There's all the family stuff at the Brookline home she shares with her partner, Jeremie Gallien , and their 7-month-old son, Theo. There's work -- a teaching assistantship for a biochemistry course at Harvard University. And there's school. After majoring in ... Read More

10

Jul2006
With researchers looking for the genes behind ADHD, it's also clear that it's a biological, inherited disorder. It is not, as had been once thought, "caused by bad parenting or weak character," said Dr. David W. Goodman, a psychiatrist and adult ADHD specialist at Johns Hopkins University School of Medicine, ... Read More

30

May2006
This article is no longer online

22

Mar2006
Just a few weeks ago, Cephalon looked like it was marching confidently toward the regulatory review of its drug for attention deficit hyperactivity disorder. Now, the Frazer, Pa., company appears to have developed a bit of a limp, as a panel of medical experts prepares to meet on Thursday to discuss the experimental ADHD drug ... Read More
March 22, 2006David W. Goodman, MD

01

Feb2006
February 1, 2006David W. Goodman, MD